Curated News
By: NewsRamp Editorial Staff
October 08, 2025
Oncotelic's Injectable Cancer Drug Boosts Bioavailability to 100%
TLDR
- Oncotelic Therapeutics' Sapu003 technology could provide a competitive advantage by dramatically increasing drug bioavailability from 10% to near 100% for breast cancer treatment.
- Oncotelic's Deciparticles technology creates sub-20nm nanoparticles that enable injectable Everolimus to achieve 80-100% bioavailability compared to 10% with oral administration.
- This advancement could significantly improve breast cancer treatment outcomes by delivering more consistent and effective medication to patients in need.
- Oncotelic's nanoparticle technology transforms a common cancer drug into an injectable form that could work up to ten times more effectively than current oral versions.
Impact - Why it Matters
This development matters because it addresses a critical limitation in cancer treatment - poor drug absorption. Current oral Everolimus only achieves about 10% bioavailability, meaning patients receive a fraction of the intended dose. By increasing bioavailability to near 100%, this technology could dramatically improve treatment outcomes for breast cancer patients, potentially leading to faster response times, more consistent therapeutic effects, and better overall survival rates. The implications extend beyond breast cancer, as this nanoparticle technology could revolutionize how many poorly-absorbed drugs are delivered, potentially transforming treatment protocols across multiple disease areas and improving patient quality of life during cancer therapy.
Summary
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company, has achieved a significant breakthrough in cancer treatment with its innovative Deciparticles™ technology. Through its joint venture GMP Bio, the company's subsidiary Sapu Nano has received clearance to begin Phase 1 clinical trials for Sapu003, an injectable form of Everolimus (marketed as Afinitor®) specifically targeting breast cancer. This development represents a major advancement in drug delivery systems, as the Deciparticles™ technology creates sub-20nm nanoparticles that dramatically improve drug bioavailability.
The potential impact of this technology is substantial, as preclinical studies have shown Sapu003 can increase the bioavailability of Everolimus from approximately 10% in its current oral pill form to an impressive 80-100% when administered as an injectable. This dramatic improvement in bioavailability could lead to significantly better, faster, and more consistent efficacy for breast cancer patients. The company's progress was highlighted in a recent BioMedWire podcast featuring Chairman and CEO Dr. Vuong Trieu, who emphasized Oncotelic's unique business model focused on de-risked, late-stage assets and accelerated development through efficient regulatory pathways.
This breakthrough represents a convergence of innovative nanotechnology and established cancer therapeutics, potentially revolutionizing how existing drugs can be optimized for better patient outcomes. The successful implementation of Deciparticles™ technology could extend beyond breast cancer treatment to improve drug delivery across multiple therapeutic areas. For those interested in following this developing story, additional details are available through the BioMedWire platform and the company's newsroom at ibn.fm/OTLC, providing comprehensive coverage of this promising advancement in cancer treatment technology.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's Injectable Cancer Drug Boosts Bioavailability to 100%
